Senzime Expands Pediatric Anesthesia Presence with New U.S. Hospital Contract
UPPSALA, Sweden, June 3, 2026 Senzime AB announced continued momentum in the pediatric anesthesia market with the award of...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
UPPSALA, Sweden, June 3, 2026 Senzime AB announced continued momentum in the pediatric anesthesia market with the award of...
UPPSALA, Sweden, June 1, 2026 Senzime AB announced the commercial launch of its next-generation TetraSens® electromyography (EMG) sensor, designed...
UPPSALA, Sweden, May 27, 2026 Senzime AB announced that the U.S. Food and Drug Administration has granted an additional...
PITTSBURGH, Pa., April 17, 2026 Xodus Medical, Inc. announced the launch of its Hot Pink Pad®, following FDA 510(k)...
